Document Detail


Segmental allergen challenge enhances chitinase activity and levels of CCL18 in mild atopic asthma.
MedLine Citation:
PMID:  23331560     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Allergic airway inflammation contributes to the airway remodelling that has been linked to increased obstruction and morbidity in asthma. However, the mechanisms by which allergens contribute to airway remodelling in humans are not fully established. CCL18, chitotriosidase (CHIT1) and YKL-40 are readily detectable in the lungs and contribute to remodelling in other fibrotic diseases, but their involvement in allergic asthma is unclear.
OBJECTIVE: We hypothesized that CCL18, YKL-40 and CHIT1 bioactivity are enhanced in allergic asthma subjects after segmental allergen challenge and are related to increased pro-fibrotic and Th2-associated mediators in the lungs.
METHODS: Levels of CCL18 and YKL-40 protein and chitotriosidase (CHIT1) bioactivity in bronchoalveolar lavage (BAL) fluid, as well as CCL18, YKL-40 and CHIT1 mRNA levels in BAL cells were evaluated in patients with asthma at baseline and 48 h after segmental allergen challenge. We also examined the correlation between CCL18 and YKL-40 levels and CHIT1 activity with the levels of other pro-fibrotic factors and chemokines previously shown to be up-regulated after allergen challenge.
RESULTS: Chitotriosidase activity and YKL-40 and CCL18 levels were elevated after segmental allergen challenge and these levels correlated with those of other pro-fibrotic factors, T cell chemokines, and inflammatory cells after allergen challenge. CCL18 and YKL-40 mRNA levels also increased in BAL cells after allergen challenge.
CONCLUSIONS AND CLINICAL RELEVANCE: Our results suggest that CCL18 and YKL-40 levels and CHIT1 activity are enhanced in allergic airway inflammation and thus may contribute to airway remodelling in asthma.
Authors:
M L Gavala; E A B Kelly; S Esnault; S Kukreja; M D Evans; P J Bertics; G L Chupp; N N Jarjour
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology     Volume:  43     ISSN:  1365-2222     ISO Abbreviation:  Clin. Exp. Allergy     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-21     Completed Date:  2013-07-01     Revised Date:  2014-03-19    
Medline Journal Info:
Nlm Unique ID:  8906443     Medline TA:  Clin Exp Allergy     Country:  England    
Other Details:
Languages:  eng     Pagination:  187-97     Citation Subset:  IM    
Copyright Information:
© 2012 Blackwell Publishing Ltd.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adipokines / metabolism
Adult
Airway Remodeling
Allergens / administration & dosage,  immunology*
Asthma / genetics,  immunology*,  metabolism*
Bronchial Provocation Tests
Bronchoalveolar Lavage Fluid / cytology,  immunology
Chemokines, CC / metabolism*
Chitinase / metabolism*
Cytokines / metabolism
Enzyme Activation
Female
Humans
Inflammation Mediators / metabolism
Lectins / metabolism
Male
Time Factors
Young Adult
Grant Support
ID/Acronym/Agency:
1UL1RR025011/RR/NCRR NIH HHS; HL-095390/HL/NHLBI NIH HHS; HL069116/HL/NHLBI NIH HHS; HL088594/HL/NHLBI NIH HHS; HL093017/HL/NHLBI NIH HHS; HL56396/HL/NHLBI NIH HHS; HL69174/HL/NHLBI NIH HHS; P01 HL088594/HL/NHLBI NIH HHS; P50 HL056396/HL/NHLBI NIH HHS; R01 HL069116/HL/NHLBI NIH HHS; R01 HL069174/HL/NHLBI NIH HHS; R01 HL093017/HL/NHLBI NIH HHS; R01 HL095390/HL/NHLBI NIH HHS; UL1 RR024146/RR/NCRR NIH HHS; UL1 RR025011/RR/NCRR NIH HHS; UL1 TR000427/TR/NCATS NIH HHS; UL1RR025011L/RR/NCRR NIH HHS; ULRR024146//PHS HHS
Chemical
Reg. No./Substance:
0/Adipokines; 0/Allergens; 0/CCL18 protein, human; 0/CHI3L1 protein, human; 0/Chemokines, CC; 0/Cytokines; 0/Inflammation Mediators; 0/Lectins; EC 3.2.1.14/Chitinase
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The 5-lipoxygenase-activating protein inhibitor, GSK2190915, attenuates the early and late responses...
Next Document:  Meconium microbiota types dominated by lactic acid or enteric bacteria are differentially associated...